With Aduhelm in tatters, the search is on for Michel Vounatsos' replacement at Biogen; David Liu, Roger Perlmutter join insitro's SAB
→ Because of the dearth of Alzheimer’s treatments, Biogen pushed aggressively to cross the regulatory goal line with aducanumab despite early trial wrap-ups and pervasive efficacy questions. The highly controversial approval of Aduhelm, and the calamitous rollout that followed, proved to be the undoing of CEO Michel Vounatsos, who was hired from within to replace George Scangos on Jan. 6, 2017. Discussions in the industry should be lively over who gets the job next at Biogen as Vounatsos will retain his position until the company finds a successor, which will be no later than Feb. 28, 2023.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
